2023
DOI: 10.1093/jscr/rjad270
|View full text |Cite
|
Sign up to set email alerts
|

Bisphosphonate-treatment of secondary chronic osteomyelitis of the jaw – a case report

Abstract: Secondary chronic osteomyelitis (SCO) is caused by bacterial infection leading to progressive jawbone destruction. Antibiotics are used as first-line treatment; surgical therapy is usually extensive and may not provide a cure. Bisphosphonates have been reported to be successful in patients with primary nonbacterial osteomyelitis, and literature indicates promising results in SCO. A 38-year-old patient presented with a progressive mandible-destruction 17 years after wisdom tooth extraction. Several treatment at… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 19 publications
0
2
0
Order By: Relevance
“…Osteogenic drugs can be categorized as water‐ or fat‐soluble drugs. [ 7 ] Water‐soluble drugs, such as bisphosphonates, can effectively inhibit osteolysis, [ 8 ] but the associated risk of jaw necrosis can last for several years, even after discontinuation. [ 8b,9 ] Moreover, the incidence of bisphosphonate‐associated osteonecrosis of the jaw varies from 1% to 10%.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Osteogenic drugs can be categorized as water‐ or fat‐soluble drugs. [ 7 ] Water‐soluble drugs, such as bisphosphonates, can effectively inhibit osteolysis, [ 8 ] but the associated risk of jaw necrosis can last for several years, even after discontinuation. [ 8b,9 ] Moreover, the incidence of bisphosphonate‐associated osteonecrosis of the jaw varies from 1% to 10%.…”
Section: Introductionmentioning
confidence: 99%
“…[ 7 ] Water‐soluble drugs, such as bisphosphonates, can effectively inhibit osteolysis, [ 8 ] but the associated risk of jaw necrosis can last for several years, even after discontinuation. [ 8b,9 ] Moreover, the incidence of bisphosphonate‐associated osteonecrosis of the jaw varies from 1% to 10%. [ 10 ] Therefore, their application in orthopedics and dental implants should be carefully considered.…”
Section: Introductionmentioning
confidence: 99%